LUNG CANCER

Osimertinib combined with chemotherapy significantly enhances overall survival in advanced EGFR-mutated non-small cell lung cancer, according to FLAURA2 trial results.

New data highlightstaletrectinib's impressive efficacy and safety in treating ROS1-positive non–small cell lung cancer, offering hope for patients.

In separate, live events, Sandip P. Patel, MD; David P. Carbone, MD, PHD; and their event participants considered treatment options for a patient with metastatic non–small cell lung cancer.

Zongertinib receives FDA breakthrough therapy designation for treating HER2-mutant non-small cell lung cancer, promising new hope for patients.

TT125-802, a promising bromodomain inhibitor, gains FDA fast track status for treating advanced non-small cell lung cancer, addressing critical patient needs.

The European Commission approves tislelizumab for neoadjuvant treatment of resectable NSCLC, enhancing survival rates and offering new hope for patients.

Treatment strategies for non–small cell lung cancer are increasingly driven by biomarker testing, making rapid and reliable biopsy an area that has attracted new interest among lung cancer specialists.

Innovent's bispecific antibody, IBI363, enters a global phase 3 trial for IO-resistant lung cancer, the first of its kind, offering new hope for this patient group.

New combination therapy shows promising results for advanced non-small cell lung cancer, offering hope for patients with limited treatment options.

The FDA designates iza-bren as a breakthrough therapy for advanced EGFR-mutant NSCLC, promising improved outcomes for patients with limited options.

During a live event, Misty D. Shields, MD, PhD, discussed using G-CSF and trilaciclib to mitigate chemotherapy-induced neutropenia in SCLC.

New data reveals sugemalimab significantly enhances survival rates in metastatic non–small cell lung cancer, establishing it as a key first-line treatment option.

Zongertinib gains FDA approval for advanced NSCLC with HER2 mutations, showcasing promising efficacy and safety in clinical trials.

Jacob Sands, MD, discusses the benefits of the arrival of Dato-DXd into the EGFR-positive non–small cell lung cancer treatment landscape and the next steps in research for this agent.

Jacob Sands, MD, discusses anaging Dato-DXd toxicities like stomatitis, eye irritation, and interstitial lung disease, which involves tailored strategies including rinses, eye drops, and close monitoring.

Jacob Sands, MD, discusses the data that support the FDA accelerated approval of Dato-DXd in EGFR-positive non–small cell lung cancer.

MAIA Biotechnology's ateganosine gains FDA fast track status, offering hope for advanced NSCLC patients with limited treatment options.

Jacob Sands, MD, discusses the inclusion of Dato-DXd into the treatment landscape of EGFR-mutant NSCLC.

During a live event, Bruna Pellini, MD, discussed the efficacy of cemiplimab in PD-L1-high non–small cell lung cancer.

Patritumab deruxtecan shows promising survival rates and manageable safety in treating leptomeningeal metastatic disease, offering hope for patients with limited options.

During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with high PD-L1.

FDA fast-tracks DB-1310, a novel HER3-targeting ADC, offering hope for advanced NSCLC patients with unmet treatment needs.

During a live event, Christine Bestvina, MD, reviewed outcomes from the phase 3 KRYSTAL-12 and CodeBreak 200 trials in the KRAS-mutated non–small cell lung cancer population.